2023 World Conference on Lung Cancer (Posters)-EP07.03. Oncological Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients

EP07.03. Oncological Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients - PDF(Abstract)

Back to course

Pdf Summary

This study compared the long-term oncological outcomes of uniportal video-assisted thoracoscopic surgery (U-VATS) versus multiportal video-assisted thoracoscopic surgery (M-VATS) lobectomy for lung cancer patients. Data from a prospective, observational study conducted between 2017 and 2019 were analyzed. The study included 174 lung cancer patients who underwent lobectomy, with 102 undergoing U-VATS and 72 undergoing M-VATS. The median follow-up time was 45 months.<br /><br />The results showed that tumor pathologic stage was the only independent prognostic factor. After adjusting for confounders, patients in the U-VATS group had similar disease-free survival (DFS), overall survival (OS), and lung cancer-specific OS compared to those in the M-VATS group. The DFS rates were 85% in the U-VATS group and 73% in the M-VATS group. The OS rates were 91% in the U-VATS group and 81% in the M-VATS group. The lung cancer-specific OS rates were 93% in the U-VATS group and 84% in the M-VATS group.<br /><br />These findings suggest that patients with lung cancer who undergo U-VATS lobectomy have similar oncological outcomes to those who undergo M-VATS lobectomy. Uniportal VATS is becoming increasingly popular as an alternative to multiportal VATS for lung cancer surgery. However, limited oncological data were previously available comparing the two approaches. This study provides valuable information on the long-term outcomes of U-VATS versus M-VATS lobectomy for lung cancer patients.

Asset Subtitle

Wei Dai

Meta Tag

Speaker Wei Dai

Topic Early-Stage NSCLC: Limited Resections & Minimally Invasive Approaches

Keywords

uniportal video-assisted thoracoscopic surgery

multiportal video-assisted thoracoscopic surgery

U-VATS

M-VATS

lobectomy

lung cancer patients

oncological outcomes

disease-free survival

overall survival

lung cancer-specific OS